equinet AG set a €112.00 ($130.23) price target on Merck KGaA (FRA:MRK) in a report released on Friday. The brokerage currently has a buy rating on the healthcare company’s stock.

MRK has been the subject of several other research reports. J P Morgan Chase & Co set a €100.00 ($116.28) target price on Merck KGaA and gave the stock a neutral rating in a research note on Friday, October 6th. Citigroup Inc. set a €123.00 ($143.02) price objective on Merck KGaA and gave the company a buy rating in a research note on Monday, September 25th. Goldman Sachs Group, Inc. (The) set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a neutral rating in a research note on Tuesday, September 19th. Kepler Capital Markets set a €119.00 ($138.37) price objective on Merck KGaA and gave the company a buy rating in a research note on Thursday, September 21st. Finally, DZ Bank AG reissued a sell rating on shares of Merck KGaA in a research report on Tuesday, July 18th. Thirteen investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Merck KGaA currently has a consensus rating of Hold and a consensus price target of €109.17 ($126.95).

Shares of Merck KGaA (FRA MRK) opened at €93.88 ($109.16) on Friday. Merck KGaA has a 52 week low of €89.00 ($103.49) and a 52 week high of €115.00 ($133.72).

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/equinet-ag-analysts-give-merck-kgaa-mrk-a-112-00-price-target/1684347.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.